Hoth Therapeutics, Inc.

NasdaqCM:HOTH Stock Report

Market Cap: US$5.8m

Hoth Therapeutics Past Earnings Performance

Past criteria checks 0/6

Hoth Therapeutics's earnings have been declining at an average annual rate of -1.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.

Key information

-1.2%

Earnings growth rate

37.0%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equity-100.2%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics extends agreement for experimental antibiotic

Jun 18

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

May 05

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

Revenue & Expenses Breakdown

How Hoth Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:HOTH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-853
30 Jun 240-753
31 Mar 240-853
31 Dec 230-843
30 Sep 230-1054
30 Jun 230-1055
31 Mar 230-1165
31 Dec 220-1165
30 Sep 220-1165
30 Jun 220-1256
31 Mar 220-1367
31 Dec 210-1478
30 Sep 210-1266
30 Jun 210-1064
31 Mar 210-1064
31 Dec 200-743
30 Sep 200-1074
30 Jun 200-1064
31 Mar 200-953
31 Dec 190-852
30 Sep 190-431
30 Jun 190-321
31 Mar 190-321
31 Dec 180-211
30 Sep 180-321

Quality Earnings: HOTH is currently unprofitable.

Growing Profit Margin: HOTH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HOTH is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.

Accelerating Growth: Unable to compare HOTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HOTH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: HOTH has a negative Return on Equity (-100.18%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies